Evidence map›Paper›PMID 37821196›Full record

ReviewRheumatic diseases clinics of North America2023

COPA Syndrome from Diagnosis to Treatment: A Clinician's Guide.

Noa Simchoni, Tiphanie P Vogel, Anthony K Shum

Open access · greenAbstract readReview
In one paragraph

Review in Rheumatic diseases clinics of North America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 14 citations in OpenAlex.

  1. Quality and Safety Intervention: Improving Care of Patients Undergoing B Cell-Targeted Therapies.The journal of allergy and clinical immunology. In practice · 2026
    Article
  2. Article
  3. Interstitial lung disease and the STING pathway.The Journal of clinical investigation · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. COPA Syndrome-From Pathogenesis to Treatment.Diagnostics (Basel, Switzerland) · 2024
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Noa SimchoniPulmonary Division, Department of Medicine, University of California, San Francisco, 555 Mission Bay Boulevard South, CVRI 284F, Box 3118, San Francisco, CA 94158, USA.
Tiphanie P VogelDivision of Rheumatology, Department of Pediatrics, Baylor College of Medicine and Center for Human Immunobiology, Texas Children's Hospital, 1102 Bates Avenue Suite 330, Houston, TX 77030, USA.
Anthony K ShumPulmonary Division, Department of Medicine, University of California, San Francisco, 555 Mission Bay Boulevard South, CVRI 284F, Box 3118, San Francisco, CA 94158, USA; Cardiovascular Research Institute, University of California, San Francisco, 555 Mission Bay Boulevard South, CVRI 284F, Box 3118, San Francisco, CA 94158, USA. Electronic address: Anthony.shum@ucsf.edu.
Mission Bio (United States) · US

Funding

ACADEMIC RHEUMATOLOGY AND CLINICAL IMMUNOLOGYT32AR007304 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DAIKH, DAVID I · 1986 to 2018
$6.0M
Unraveling the molecular mechanisms of impaired central tolerance in COPA syndromeR01AI168299 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Anthony Shum · 2022 to 2026
$3.3M
Academic Rheumatology and Clinical ImmunologyT32AR079068 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jinoos Yazdany, JULIE ZIKHERMAN · 2021 to 2026
$2.5M
Defining the Role of Thymic Tolerance in the Pathogenesis of the COPA syndromeR01AI137249 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHUM, ANTHONY · 2018 to 2022
$2.4M
Defining the molecular mechanisms of COPA syndrome through computational modeling and functional studiesR21AI160107 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHUM, ANTHONY · 2021 to 2022
$448k
NIAID NIH HHS R01 AI137249NIAID NIH HHS R01 AI168299NIAID NIH HHS R21 AI160107NIAMS NIH HHS T32 AR007304NIAMS NIH HHS T32 AR079068
6 · The paper itself

Abstract

COPA syndrome is a recently described autosomal dominant inborn error of immunity characterized by high titer autoantibodies and interstitial lung disease, with many individuals also having arthritis and nephritis. Onset is usually in early childhood, with unique disease features including alveolar hemorrhage, which can be insidious, pulmonary cyst formation, and progressive pulmonary fibrosis in nonspecific interstitial pneumonia or lymphocytic interstitial pneumonia patterns. This review explores the clinical presentation, genetics, molecular mechanisms, organ manifestations, and treatment approaches for COPA syndrome, and presents a diagnostic framework of suggested indications for patient testing.

Indexed as

Lung Diseases, InterstitialChild, PreschoolHumansAlveolar hemorrhageArthritisAutoantibodyChildCOPA syndromeInfantInterstitial lung diseaseNephritis

Identifiers

PMID37821196
PMCPMC10866555
OpenAlexW4384944689

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.